3rd Peptide-Based Therapeutics Summit Opens in Boston (April 28-30) with Pinnacle, Unnatural Products, Daiichi Sankyo as Featured Speakers
The 3rd Peptide-Based Therapeutics Summit opened today in Boston, running April 28-30 with the industry's only dedicated platform for next-generation peptide discoveries. Featured industry news being presented includes Pinnacle Medicines' $89M Series B for oral peptide therapeutics, J&J's FDA approval of ICOTRYDE™, Daiichi Sankyo's Meddenovo Mexa AI cyclic peptide collaboration, and Unnatural Products' $45M Series B for synthetic macrocyclic peptides (on top of last year's $1.7B Novartis deal). The summit reflects the rapid growth of peptides as a disruptive third modality alongside small molecules and biologics.